

• **Name:**

**Jun Ho Jang**

• **Affiliation/Current Position:**

**Samsung Medical Center, Sungkyunkwan University School of Medicine**

• **Country:**

**Seoul, Republic of Korea**

• **ICKSH2022 Presentation Title:**

**Korea Treatment Guideline for Aplastic Anemia**

• **Educational Background:**

- 1986-1992** Yonsei University College of Medicine, Seoul, Korea
- 1992** M.D. No.46514, Korea
- 1998-2000** Master Degree, Graduate School, Yonsei University, Seoul, Korea
- 2000** Korean Board of Internal Medicine No.6448
- 2000-2002** Ph.D Degree, Graduate School, Yonsei University, Seoul, Korea
- 2002-2004** Post-Doctoral fellowship, University of Michigan, Ann Arbor, USA

• **Professional Experiences:**

- 1995-1996** Internship  
Severance Hospital,  
Yonsei University College of Medicine,  
Seoul, Korea
- 1996-2000** Residency, Internal Medicine  
Severance Hospital,  
Yonsei University College of Medicine,  
Seoul, Korea
- 2000-2002** Fellowship, Hematology-Oncology  
Severance Hospital,  
Yonsei University College of Medicine,  
Seoul, Korea
- 2002-2004** Post-Doctoral Research fellowship  
University of Michigan  
Ann Arbor, Michigan, USA
- 2004-2007** Assistant professor,  
Department of Hematology-Oncology  
Ajou University School of Medicine, Suwon, Korea

- 2007-2013** Associate Professor  
Division of Hematology-Oncology  
School of Medicine  
SungKyunKwan University, Samsung Medical Center, Seoul, Korea
- 2014-** Professor  
Division of Hematology-Oncology  
School of Medicine  
SungKyunKwan University, Samsung Medical Center, Seoul, Korea
- 2019-** Chairman of the commission  
The Korean Society of Hematology aplastic anemia working Party

### • Professional Organizations

The Korean Society of Hematology  
The Korean Society of Blood and Marrow Transplantation  
The Korean Society on Thrombosis and Hemostasis  
The Korean Association of Internal Medicine  
The Korean Society for Patient Blood Management  
American Society of Hematology (ASH)  
The European Hematology Association (EHA)

### • Main Scientific Publications:

1. Roboz GJ, Döhner H, Pocock C, Dombret H, Ravandi F, Jang JH, Selleslag D, Mayer J, Martens UM, Liesveld J, Bernal T, Wang MC, Yu P, Shi L, Guo S, La Torre I, Skikne B, Dong Q, Braverman J, Nehme SA, Beach CL, Wei AH. Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial. *Haematologica*. 2021 Sep 23. (Co-Author)
2. Kang D, Kim IR, Choi HJ, Jung CW, Yoon SS, Kim JS, Lee CH, Jang JH, Cho J. Association between body image dissatisfaction and poor quality of life and depression among patients with hematopoietic stem cell transplantation. *Support Care Cancer*. 2021 Jul;29(7):3815-3822. (Corresponding author)
3. Kobayashi Y, Oh I, Miyamoto T, Lee WS, Iida H, Minami H, Maeda Y, Jang JH, Yoon SS, Yeh SP, Tran Q, Morris J, Franklin J, Kiyoi H. Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. *Asia Pac J Clin Oncol*. 2021 Jun 29. (Co-Author)
4. Jung HA, Jung CW, Jang JH. Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome. *Korean J Intern Med*. 2021 Mar;36(2):413-423. (Corresponding author)

5. Steensma DP, Fenaux P, Van Eygen K, Raza A, Santini V, Germing U, Font P, Diez-Campelo M, Thepot S, Vellenga E, Patnaik MM, Jang JH, Varsos H, Bussolari J, Rose E, Sherman L, Sun L, Wan Y, Dougherty S, Huang F, Feller F, Rizo A, Platzbecker U. Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. *J Clin Oncol*. 2021 Jan 1;39(1):48-56. (Co-Author)
6. Jang JH, Tomiyama Y, Miyazaki K, Nagafuji K, Usuki K, Uoshima N, Fujisaki T, Kosugi H, Matsumura I, Sasaki K, Kizaki M, Sawa M, Hidaka M, Kobayashi N, Ichikawa S, Yonemura Y, Enokitani K, Matsuda A, Ozawa K, Mitani K, Lee JW, Nakao S. Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study. *Br J Haematol*. 2021 Jan;192(1):190-199. (First Author)
7. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. *N Engl J Med*. 2020 Aug 13;383(7):617-629 (Co-Author)
8. Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Kizil Çakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. *N Engl J Med*. 2020 Dec 24;383(26):2526-2537 (Co-Author)
9. Jang JH, Kim Y, Park S, Kim K, Kim SJ, Kim WS, Jung CW, Lee J, Lee SH. Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea. *PLoS Med*. 2020 Jun 8;17(6):e1003091. (First Author)
10. Lee JW, Lee SE, Jung CW, Park S, Keta H, Park SK, Kim JA, Oh IH, Jang JH. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. *Lancet Haematol*. 2019 Nov;6(11):e562-e572. (Corresponding author)
11. Jung KS, Kim YJ, Kim YK, Park SK, Kim HG, Kim SJ, Park J, Choi CW, Do YR, Kim I, Park S, Mun YC, Jeong SH, Kim MK, Yi HG, Chang MH, Kim SY, Lee JH, Jang JH. Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System. *Clin Lymphoma Myeloma Leuk*. 2019 Oct;19(10):656-664. (Corresponding author)
12. Park S, Choi EK, Kim IR, Cho J, Jang JH. Comparison of quality of life and

depression between hematopoietic stem cell transplantation survivors and their spouse caregivers. *Blood Res.* 2019 Jun;54(2):137-143. (Corresponding author)

13. Sakurai M, Jang JH, Chou WC, Kim JS, Wilson A, Nishimura JI, Chiou TJ, Kanakura Y, Lee JW, Okamoto S. Comparative study on baseline clinical characteristics of Asian versus non-Asian patients with paroxysmal nocturnal hemoglobinuria. *Int J Hematol.* 2019 Oct;110(4):411-418. (Co-First Author)
14. Kim JS, Cheong JW, Mun YC, Jang JH, Jo DY, Lee JW; Aplastic Anemia Working Party of the Korean Society of Hematology. Clinical implication of renal dysfunction during the clinical course in patients with paroxysmal nocturnal hemoglobinuria: a longitudinal analysis. *Ann Hematol.* 2019 Oct;98(10):2273-2281. (Co-Author)
15. Abdullah HR, Ang AL, Froessler B, Hofmann A, Jang JH, Kim YW, Lasocki S, Lee JJ, Lee SY, Lim KKC, Singh G, Spahn DR, Um TH; Asia-Pacific PBM Expert Consensus Meeting Working Group. Getting patient blood management Pillar 1 right in the Asia-Pacific: a call for action. *Singapore Med J.* 2019 May 2. doi: 10.11622/smedj.2019037. [Epub ahead of print] (Co-First Author)
16. Frey N, Jang JH, Szer J, Illés Á, Kim HJ, Ram R, Chong BH, Rowe JM, Borisenkova E, Liesveld J, Winer ES, Cherfi A, Aslanis V, Ghaznawi F, Strickland S. Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. *Lancet Haematol.* 2019 Mar;6(3):e122-e131. (Co-First Author)